Stapokibart

Stapokibart (CM310) is a humanized monoclonal antibody targeting IL-4Rα (KD values of 0.25 nM, 1.50 nM, and 2.75 nM for human, cynomolgus monkey, and rat IL-4Rα, respectively) . Stapokibart effectively blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart reduces IL-4 and IL-13 mRNA, inhibits CD23 upregulation, and inhibits IL-4 and IL-13-induced STAT6 activation. Stapokibart improves inflammation (airway inflammation, rhinitis, dermatitis) [1][2].

Product Specifications

CAS Number

[2734715-10-5]

Product Name Alternative

CM310

UNSPSC

12352203

Target

Interleukin Related; STAT

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/stapokibart.html

Purity

99.37

Solubility

10 mM in DMSO

Smiles

[Stapokibart]

Molecular Weight

(144.3 kDa)

References & Citations

[1]Yuan Zhang, et al. Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1) : a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial. EClinicalMedicine. 2023 Jul 5:61:102076.|[2]Liu W, et al. Stapokibart (CM310) targets IL-4Rα for the treatment of type 2 inflammation. iScience. 2024 Aug 13;27 (9) :110721.